Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

A technology of sirolimus and complexes, applied in the field of complexes of sirolimus and its derivatives, its preparation and pharmaceutical compositions containing them, can solve the problems of complicated and expensive preparation methods, and achieve Reduced fed/fasted effects, increased solubility, reduced dose effects

Inactive Publication Date: 2017-02-22
DRUGGABILITY TECH IP HOLDCO
View PDF37 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, current preparation methods are complex and expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
  • Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
  • Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0110] Such as figure 1 As shown, several pharmaceutically acceptable complexing agents and pharmaceutically acceptable excipients and combinations thereof were tested in order to select formulations with instantaneous redispersibility. One of the examples showing an acceptable level of redispersibility was selected for further analysis.

[0111] Polyvinylpyrrolidone as complexing agent and sodium lauryl sulfate as pharmaceutically acceptable excipient were selected to form complexed sirolimus formulations with improved bulk properties.

[0112] The ratio of the selected complexing agent and pharmaceutically acceptable excipients (polyvinylpyrrolidone and sodium lauryl sulfate) was optimized, making some nuances during the manufacturing process to change some characteristics of the product.

[0113] Colloidal solutions of complexed formulations of sirolimus according to the invention were prepared by continuous flow precipitation in a flow apparatus. 100 mg sirolimus and 300...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dube Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. Furthermore, the complex of the present invention possesses exceptional stability as a redispersed solution allowing the development of liquid based formulation for transdermal and other topical applications. The invention also relates to methods of formulating and manufacturing complex according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.

Description

technical field [0001] The present invention relates to stable complexes having controlled particle size, increased apparent solubility and increased dissolution rate, comprising the active compound sirolimus or derivatives thereof, for use in recipients of renal transplantation Prevention of organ rejection in patients with psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé syndrome, chronic erosive oral lichen planus, Early cutaneous T-cell lymphoma, treatment of autoimmune active anterior uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin disease (dermatitis , including psoriasis and lichen planus), congenital nail hypertrophy, and for inhibition of angiogenic pathways. More specifically, the complexes of the present invention have increased apparent solubility, permeability and enhanced biological properties, including signi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/10A61K47/20A61K47/32A61K31/436A61P17/06A61P35/00A61P1/02A61P37/06A61P37/02A61P27/02A61P3/10A61P7/10A61P9/14A61P17/00A61P43/00
CPCA61K31/436A61K47/10A61K47/20A61K47/32A61K47/58A61K47/6933A61P1/02A61P13/12A61P17/00A61P17/06A61P27/02A61P27/04A61P27/10A61P29/00A61P35/00A61P35/02A61P37/02A61P37/06A61P43/00A61P7/10A61P9/00A61P9/14A61P3/10A61K9/51
Inventor E·R·安吉T·索里莫斯R·B·卡帕蒂Z·芬尼维斯Z·奥特沃斯L·摩尔纳H·格拉维纳斯G·菲利普西K·费伦兹G·海尔托维茨
Owner DRUGGABILITY TECH IP HOLDCO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com